Sugi Predict

Sugi Predict / Compounds / SCHEMBL2492947

SCHEMBL2492947

SCHEMBL2492947

CS(=O)(=O)OC1CCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ NPC1 O15118 2/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ CYP2C19 P33261 1/20 0.55
▸ F13A1 P00488 4/20 0.50
▸ TGM2 P21980 4/20 0.50
▸ TGM1 P22735 4/20 0.50
▸ HTT P42858 1/20 0.50
▸ PDE4B Q07343 1/20 0.50
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ GRIN2B Q13224 4/20 0.47
▸ MMP1 P03956 2/20 0.47
▸ MMP3 P08254 2/20 0.47
▸ MMP7 P09237 2/20 0.47
▸ MMP9 P14780 2/20 0.47
▸ MMP13 P45452 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15084704 1.00 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9ACYP2C19F13A1
SCHEMBL1103933 1.00 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9ACYP2C19F13A1
SCHEMBL28408148 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACYP2C19F13A1
SCHEMBL21806124 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACYP2C19F13A1
SCHEMBL711419 0.93 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACYP2C19F13A1
SCHEMBL375302 0.93 SMN1; SMN2 (0.64) SMN1; SMN2NPC1RAB9ACYP2C19F13A1
SCHEMBL18592896 0.91 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9ACYP2C19F13A1
SCHEMBL504558 0.88 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9ACYP2C19F13A1
SCHEMBL3620573 0.88 SMN1; SMN2 (0.58) SMN1; SMN2NPC1RAB9ACYP2C19F13A1
SCHEMBL16095295 0.87 SMN1; SMN2 (0.56) SMN1; SMN2NPC1RAB9ACYP2C19F13A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270213-A1 PI3Ka INHIBITORS PIKAVATION THERAPEUTICS, INC. 2025-08-28 — — US disclosed
CN-119654321-A PI3K alpha inhibitors 突触活化疗法股份有限公司 2025-03-18 — — CN disclosed
CN-114957182-B USP8 inhibitor containing flavone skeleton structure and application thereof 中国药科大学 2024-03-15 — — CN disclosed
CN-114957182-A USP8 inhibitor containing flavone skeleton structure and application thereof 中国药科大学 2022-08-30 — — CN disclosed
US-20210355115-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2021-11-18 — — US disclosed
CN-113056455-A Isoxazole carboxamide compounds and uses thereof 诺华股份有限公司 2021-06-29 — — CN disclosed
CN-107912040-B Pyrrolidine amide compounds as histone demethylase inhibitors 基因泰克公司 2021-04-06 — — CN disclosed
US-10022354-B2 Pyrrolidine amide compounds as histone demethylase inhibitors GENENTECH, INC. (US) 2018-07-17 — — US disclosed
US-10022354-B2 Pyrrolidine amide compounds as histone demethylase inhibitors GENENTECH, INC. (US) 2018-07-17 — — US disclosed
US-20170312252-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS WUXI APPTEC (SHANGHAI) CO. LTD (CN) 2017-11-02 — — US disclosed
US-20170312252-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS WUXI APPTEC (SHANGHAI) CO. LTD (CN) 2017-11-02 — — US disclosed
EP-3204379-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS Genentech, Inc. (US) 2017-08-16 — — EP disclosed
WO-2016057924-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS GENENTECH, INC. (US) 2016-04-14 — — WO disclosed
WO-2016057924-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS GENENTECH, INC. (US) 2016-04-14 — — WO disclosed
US-8030501-B2 Process for producing optically active 3-amino nitrogen-containing compounds KANEKA CORPORATION (JP) 2011-10-04 — — US disclosed
US-20090326246-A1 Method for Production of Optically Active 3-Amino-Nitrogenated Compound KANEKA CORPORATION (JP) 2009-12-31 — — US disclosed
EP-2050735-A1 METHOD FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-NITROGENATED COMPOUND Kaneka Corporation (JP) 2009-04-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355115-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF SLC26A4, ALDH5A1, SLC8B1 SMN1; SMN2 743/4885NPC1 1681/4885RAB9A 1326/4885
US-20170312252-A1 PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS KDM5A, KDM5C, KDM5B SMN1; SMN2 2278/4885NPC1 2561/4885RAB9A 3251/4885
US-20090326246-A1 Method for Production of Optically Active 3-Amino-Nitrogenated Compound PNMT, NPEPPS, GNMT SMN1; SMN2 992/4885NPC1 2790/4885RAB9A 1721/4885
US-10022354-B2 Pyrrolidine amide compounds as histone demethylase inhibitors KDM5A, KDM5C, KDM1B SMN1; SMN2 2301/4885NPC1 2297/4885RAB9A 3142/4885
US-20250270213-A1 PI3Ka INHIBITORS PIK3CA, PIK3C2A, PIK3R5 SMN1; SMN2 1804/4885NPC1 701/4885RAB9A 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.